Sichuan Huiyu Pharmaceuticals Co. Ltd. and Sichuan Huiyu Seacross Pharma Technology Ltd. have patented new Son of sevenless homolog 1 (SOS1) inhibitors potentially useful for the treatment of cancer and Noonan syndrome.